Table 4 Comparison of therapeutic embolization, preventive embolization and diagnostic angiography groups.

Age (y), M (SD)

75.7 (12.9)

69.8 (8.1)

73.3 (9.5)

0.158

Sex (F/M)

22/5

13/1

16/3

0.810

Time from onset of COVID-19 to bleeding (days), M (SD)

13.7 (5.3)

14.1 (3.3)

15.5 (4.9)

0.524

Time from the start of anticoagulant therapy

to hematoma detection (days), M (SD)

8.7 (5.7)

8.3 (3.3)

11.6 (5.2)

0.146

Anticoagulant therapy, n (%)

Unfractionated heparin

1 (3.7)

0

0

Low molecular weight heparin

23 (85.2)

12 (85.7)

17 (89.5)

Novel Oral Anticoagulants (NOAC)

1 (3.7)

0

0

Combination

2 (7.4)

2 (14.3)

2 (10.5)

ASA, M (SD)

3.8 (0.7)

3.7 (0.6)

3.7 (0.8)

NEWS 2, M (SD)

5.1 (3.5)

4.6 (1.7)

6.0 (3.4)

APACHE-2

(n is number of patients in ICU), M (SD)

n = 21

18.7 (8.1)

n = 7

22.7 (10.1)

n = 13 19 (6.5)

Vasopressor support before procedure (n = 22),

n (%)

12 (44.4)

3 (21.4)

7 (36.8)

COVID-19 severity, n (%)

Moderate

8 (29.6)

8 (57.1)

3 (15.8)

Severe

16 (59.3)

4 (28.6)

12 (63.2)

Extremely severe

3 (11.1)

2 (14.3)

4 (21)

Hematoma location, (n)

Anterior

abdominal wall

19

14

8

Retroperitoneal space

6

0

3

Thoracic wall

2

0

8

Hematoma volume (ml), M (SD)

1022.2 (644.9)

1224.1 (790.5)

887 (483.2)

Hemoglobin (g/l) before angiography, M (SD)

76.4 (19.6)

94.2 (28.6)

82.3 (26.1)

Time from hematoma detection before AG (min), M (SD)

220.4 (328.4)

371.9 (249.8)

348.1 (409.6)

Duration of procedure (min), M (SD)

66.5 (43.1)

57.4 (20.8)

40.5 (28.2)

Subsequent open surgery, n (%)

1 (3.7)

2 (14.3)

2 (10.5)

Artery dissection, n (%)

2 (7.4)

0

0

Mortality, n (%)

11 (40.8)

4 (28.6)

11 (57.9)